Core Viewpoint - Tongrentang Medical Investment Co., Ltd. is making a third attempt to submit its prospectus for an IPO on the Hong Kong Stock Exchange, with CICC as the sole sponsor, which could lead to the establishment of the fourth listed company under the Tongrentang Group [1][3] Group 1: Company Overview - Tongrentang Medical has become the largest non-public Chinese traditional medicine hospital group in terms of outpatient and inpatient visits, holding a market share of 1.7% [3] - The company reported revenues of 911 million yuan, 1.153 billion yuan, and 1.175 billion yuan for the years 2022, 2023, and 2024, respectively, with adjusted net profits of -9.23 million yuan, 47.87 million yuan, and 61.73 million yuan [3] - The acquisition of Sanxi Tang has significantly contributed to Tongrentang Medical's performance, with revenues from Sanxi Tang accounting for 21.9%, 31.2%, and 31.8% of total revenues in 2022, 2023, and 2024, respectively [3][4] Group 2: Financial Performance - Sanxi Tang contributed to Tongrentang Medical's gross profit, with figures of 64 million yuan, 96.9 million yuan, and 91.8 million yuan for the years 2022, 2023, and 2024, representing 44.8%, 44.6%, and 41.3% of the total gross profit [3] - The gross margin for Tongrentang Medical has been declining, with rates of 39.6%, 20.2%, and 17.9% for the years 2022, 2023, and 2024, respectively [7] Group 3: Strategic Acquisitions and Partnerships - In 2024, Sanxi Tang obtained exclusive sales rights for the Tongrentang brand's An Gong Niu Huang Wan series products to retailers in Zhejiang Province, which is expected to boost sales [6] - The sales revenue from An Gong Niu Huang Wan for 2024 is projected to be 73.149 million yuan, with Sanxi Tang's wholesale revenue from this product accounting for 31% of Tongrentang Medical's health products sales [6][7] Group 4: Shareholder Dynamics - Following multiple shareholding changes, as of March 2024, Tongrentang Medical holds a 75% stake in Sanxi Tang, with the original controlling shareholders also retaining a stake [4][5] - The original controlling shareholders, Zhu Zhibiao and Pan Songqin, became shareholders of Tongrentang Medical through capital increase in March 2024, holding a combined 3.87% stake [5]

Group 1 - The article provides an overview of the investment activities of Hong Kong-listed companies on August 11, 2025, including new stock activities, earnings announcements, shareholder meetings, and dividend distributions [1] Group 2 - New stock activities include companies such as ZhiNuo Pharmaceutical-B (currently in the IPO process) and Zhonghui Biotechnology-B (listing date) [1] - Earnings announcements are scheduled for companies like Baosheng International, Yuanyuan Group, and Kang Shifu Holdings among others [1] - Shareholder meetings will be held for companies including Huatai Textile, Shandong Gold, and Sichuan Chengyu Expressway [1] - Dividend distributions are noted for companies like Jianbei Miao Miao and Kangnait Optical, with specific ex-dividend and payment dates mentioned [1]

火热七月，激情无限。 2025年"同仁堂杯"职工职业技能竞赛暨第四届全国中药传统名堂职业技能竞赛拉开帷幕，在北京同仁堂 科技发展股份有限公司（以下简称"科技公司"）的分赛场内，药香四溢，手匾律动，搓丸板下一粒粒 光、亮、圆、齐的蜜丸次第滚出。交流切磋，比拼技艺，成为这个夏日里科技公司传承中医药匠心的生 动注脚。 据悉，本次赛事，科技公司报名参赛的选手传统中药制作项目35人，中药鉴别项目100人，经过角逐， 参加中药鉴别实操初赛的选手35人，参加传统中药制作实操初赛的选手18人。 据了解，同仁堂集团赛事组委会在保留中药鉴别项目的基础上，新增了传统中药制作项目，这一变化可 谓意义深远：传统中药制作是中医药传承千年的精髓所在，包含泛丸制作、中药切片、蜜丸制作三个部 分，每一个部分都是中医药从药材到药品的关键环节。新增项目，旨在加强传统中药技艺在当今时代的 发展，进一步推动中医药传统技艺的传承与发展。 从实际操作的角度来看，传统中药制作项目的增加无疑给选手们增加了更大的难度和挑战性——在日常 工作中，由于分工的细化，绝大多数选手往往只专注于制作技艺中的一项，要同时能够应对泛丸制作、 中药切片、蜜丸制作三项考核内容，显 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京同仁堂科技發展股份有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 內資股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 652,080,000 RMB | | 1 | RMB | | 652,080,000 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 652,080,000 RMB | | 1 | RMB | | 652,080,000 | | 2. 股份分類 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本通告全部或任何部份內容而產生或因依賴該等內 容而引致之任何損失承擔任何責任。 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：1666） 股東特別大會通告 茲通告北京同仁堂科技發展股份有限公司（「本公司」）謹訂於二零二五年八月十八 日（星期一）下午一時三十分假座中華人民共和國（「中國」）北京市豐台區南三環中路20 號舉行股東特別大會（「股東特別大會」），藉以考慮及酌情通過下列決議案： – 1 – 1. 批准張春友先生為本公司第九屆董事會之執行董事及董事會建議的其薪酬； 並授權董事會與其訂立董事服務合約。 2. 批准溫凱婷女士為本公司第九屆董事會之執行董事及董事會建議的其薪酬； 並授權董事會與其訂立董事服務合約。 3. 批准董事會建議的本公司執行董事張毅先生之薪酬。 4. 批准董事會建議的本公司職工董事之薪酬。 5. 批准修訂本公司之股東會議事規則。 6. 批准修訂本公司之董事會議事規則。 特別決議案 7. 批准修訂本公司之公司章程（ ...

此乃要件 請即處理 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示概不會就因本通函全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承 擔任何責任。 閣下如對本通函任何方面或應採取之行動有任何疑問，應諮詢 閣下之股票經紀或其他註冊證券交易商、銀行經 理、律師、專業會計師或其他專業顧問。 閣下如已將名下之北京同仁堂科技發展股份有限公司股份全部售出或轉讓，應立即將本通函及隨附之代理人委 任表格送交買主或承讓人或經手賣或轉讓之銀行、持牌證券交易商或其他代理商，以便轉交買主或承讓人。 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 （股份代號：1666） 建議委任董事及釐定董事之薪酬； 董事會函件載於本通函第3頁至第9頁。本公司謹訂於二零二五年八月十八日（星期一）下午一時三十分假座中國 北京市豐台區南三環中路20號舉行股東特別大會，大會通告載於本通函第127頁至第129頁。 （包括取消監事會及監事及設立職工董事）； 建議修訂股東會議事規則； 如 閣下擬委任代理人出席股東特別大會，務請儘快且無論如何須於股東特別大 ...

Group 1 - The core viewpoint of the article highlights the successful implementation of an intelligent financial system by Tongrentang Technology Company, which integrates cost data and enhances risk management and fund control capabilities [1][3] - The company received the "Demonstration Unit of Financial Digital Transformation for Chinese Enterprises" award at the 19th China CFO Forum, showcasing its innovative attempts in financial capability transformation [3] - The intelligent financial project addresses challenges such as fragmented business operations and inefficient fund management, which previously hindered decision-making speed and resource allocation [3][4] Group 2 - The digital platform integrates various data including funds, taxes, budgets, and costs, enabling consolidated management and intelligent accounting across the entire system [4] - The system allows for precise cost tracking of production batches, reducing the time required for cost accounting from 4 hours to just 15 minutes, and features a cost visualization function for detailed cost breakdowns [4] - The financial system provides real-time monitoring of fund inflows and outflows, enhancing decision-making confidence during operational meetings [4][5] Group 3 - The unified accounting standards and real-time fund monitoring enable the headquarters to exercise strong control over the entire system, transforming financial data into a strategic resource for high-quality development [5] - The company has deployed nearly a hundred analytical models based on the system platform, covering various business units such as budget analysis, production-sales coordination, profit insights, and efficiency evaluation [5]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈全 部或任何部份內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 北京同仁堂科技發展股份有限公司（「本公司」）董事（「董事」）會（「董事會」） 謹此宣佈，於二零二五年七月十七日舉行之董事會會議已通過相關決議案，建 議對本公司之公司章程（「公司章程」）進行修訂（包括取消本公司監事會 （「監事會」）及監事（「監事」）及設立職工代表董事）。建議修訂公司章程 須待股東於本公司股東特別大會（「股東特別大會」）以特別決議案的方式批准後 生效。 为了與修訂後的公司章程相匹配并进行其他常规性修改，董事會亦決議建議對本 公司股東會議事規則（「股東會議事規則」）及董事會議事規則（「董事會議事 規則」）作出若干修訂。建議修訂股東會議事規則及董事會議事規則須待股東 於股東特別大會分別以普通決議案的方式批准後生效。 有關決議案將提交股東特別大會以供本公司股東（「股東」）考慮及批准。載 有上述有關決議案詳情之通函將適時寄發予股東。 （股份代號：1666） (1) 建議修訂公司章程（包括取消監事會 ...

Core Insights - The demand for summer heat-relief products has surged since July, with companies like Beijing Tongrentang Technology Development Co., Ltd. ramping up production of traditional remedies such as Ren Dan and Huo Xiang Zheng Qi Shui to meet market needs [1][3] Group 1: Product Development and Production - The company has adjusted its production capacity and efficiency to ensure timely supply of summer health products, including increasing staffing for summer medication production [1] - Modern and intelligent equipment has been integrated into the production process, such as the introduction of centrifugal coating granulators for standardized management of production processes [3] - Six types of summer health products, including Ren Dan and Huo Xiang Zheng Qi Shui, have been fully distributed to pharmacies nationwide, ensuring consumer safety and health during the summer [3] Group 2: Product Features and Benefits - Ren Dan is designed to alleviate discomfort caused by high temperatures, utilizing ingredients like menthol and borneol to provide a cooling effect [7] - Huo Xiang Zheng Qi Shui addresses issues related to heat and humidity, using a classic formula that includes Huo Xiang as the main ingredient to relieve symptoms like headaches and gastrointestinal discomfort [5] - Sheng Mai Yin serves as an energy supplement for those who sweat excessively in summer, featuring ingredients like red ginseng and wheat to nourish and hydrate [9]

同仁堂目前已有三家上市公司，包括： 1）1997年6月25日在上海证交所上市的同仁堂股份（600085.SH），按35.52元人民币计算，市值为487亿元人民币，是同仁 堂体系中的核心企业，业务涵盖中成药的研发、生产与销售，拥有众多知名中成药产品。 2）2000年在香港创业板上市后于2010年7月9日转到主板上市的同仁堂科技（01666.HK），为A股上市公司的子公司，按 4.90港元计，市值为63亿港元。在中国内地及香港生产和销售中成药。 3）在港交所上市的同仁堂国药（03613.HK），为同仁堂科技的子公司，A股上市公司的孙公司，于2004年由同仁堂科技分 拆成立，是同仁堂推动中医药国际化的海外发展平台。于2013年在香港创业板上市，2018年转主板上市。按8.90港元计， 市值为76亿港元。在内地批发保健品，通过香港分部的零售店铺销售中药和保健品及提供中医诊断服务、批发中药，并管 理使用"同仁堂"品牌的海外实体。 这三家公司均从事中医健康产品的生产和销售。 接下来，同仁堂又将增加一家上市公司，旗下医疗养老业务——北京同仁堂医养投资股份有限公司（下称"同仁堂医 养"），已于6月30日向港交所提交了上市申请 ...